1. Home
  2. VCIG vs OGEN Comparison

VCIG vs OGEN Comparison

Compare VCIG & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

HOLD

Current Price

$0.82

Market Cap

2.9M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.57

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCIG
OGEN
Founded
2013
1996
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.7M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
VCIG
OGEN
Price
$0.82
$0.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
148.5K
41.8K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.11
52 Week High
$23.40
$9.16

Technical Indicators

Market Signals
Indicator
VCIG
OGEN
Relative Strength Index (RSI) 33.93 38.71
Support Level $0.68 $0.57
Resistance Level $1.27 $1.02
Average True Range (ATR) 0.06 0.04
MACD 0.02 -0.00
Stochastic Oscillator 3.32 8.07

Price Performance

Historical Comparison
VCIG
OGEN

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: